Compare DexCom, Inc. (DXCM) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs MPLX LP — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while MPLX LP trades at $56.3 (market cap $58.11B). The key difference: MPLX LP is the larger of the two by market cap, and MPLX LP pays a 7.51% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MPLX | |
|---|---|---|
Market Cap | $31.86B | $58.11B |
Volume | 3,607,070 | 687,483 |
Sector | Health | Energy |
52-Week High | $92.34 | $60.51 |
52-Week Low | $54.84 | $47.80 |
Typical Hold Time | 62 Days | — |
Enterprise Value | $31.32B | $83.22B |
Dividend Yield | — | 7.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
MPLX trades at $57.32, up 0.47% with a bearish technical signal despite strong fundamentals. The company maintains robust profitability with 40.45% net income margin and 33.95% ROE, supported by $4.91B net income in 2025. Recent earnings show mixed results with a Q4 2025 beat but Q1 and Q2 2026 misses. Analyst consensus remains strongly bullish with 19 buy ratings and a $63.80 price target, representing 11.3% upside potential.
The investment case balances strong cash flow generation and dividend stability against energy market volatility risks. MPLX's fee-based midstream model provides revenue resilience, though technical indicators suggest near-term pressure. The 67.86% buy rating consensus indicates Wall Street confidence in the company's ability to maintain distribution growth despite recent earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
